| Colorectal Cancer Treatments and Studies | Lifetime | 14 | US 8 | 99.89 |
| Genetic factors in colorectal cancer | Lifetime | 26 | US 14 | 99.81 |
| Cancer Genomics and Diagnostics | Lifetime | 80 | US 50 | 99.77 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 110 | US 43 | 99.52 |
| Cancer Treatment and Pharmacology | Lifetime | 160 | US 89 | 99.49 |
| Gastric Cancer Management and Outcomes | Lifetime | 264 | US 95 | 99.33 |
| Lung Cancer Treatments and Mutations | Lifetime | 260 | US 137 | 99.32 |
| Melanoma and MAPK Pathways | Lifetime | 68 | US 36 | 99.21 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 431 | US 227 | 99.01 |
| Colorectal and Anal Carcinomas | Lifetime | 167 | US 82 | 98.66 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 708 | US 311 | 98.42 |
| Cancer Research and Treatments | Lifetime | 441 | US 262 | 97.63 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 155 | US 28 | 96.19 |
| Colorectal Cancer Surgical Treatments | Lifetime | 518 | US 150 | 97.66 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 321 | US 191 | 97.39 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 813 | US 212 | 97.12 |
| Colorectal Cancer Screening and Detection | Lifetime | 884 | US 387 | 97.04 |
| HER2/EGFR in Cancer Research | Lifetime | 783 | US 349 | 96.89 |
| Cancer Genomics and Diagnostics | 2021-2025 | 16 | US 9 | 99.77 |
| Genetic factors in colorectal cancer | 2021-2025 | 6 | US 1 | 99.78 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 11 | US 3 | 99.83 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 132 | US 49 | 99.13 |
| Cancer Treatment and Pharmacology | 2021-2025 | 69 | US 26 | 98.57 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 387 | US 155 | 98.51 |
| Melanoma and MAPK Pathways | 2021-2025 | 29 | US 11 | 98.56 |
| Cancer Research and Treatments | 2021-2025 | 64 | US 17 | 95.82 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 347 | US 77 | 97.11 |
| Colorectal and Anal Carcinomas | 2021-2025 | 119 | US 41 | 96.00 |
| Immunotherapy and Immune Responses | 2021-2025 | 961 | US 317 | 90.98 |
| HER2/EGFR in Cancer Research | 2021-2025 | 712 | US 239 | 88.86 |
| Cancer Cells and Metastasis | 2021-2025 | 989 | US 247 | 83.32 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 312 | US 116 | 77.05 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 848 | US 300 | 68.74 |
| Chemokine receptors and signaling | 2021-2025 | 748 | US 152 | 53.44 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 604 | US 253 | 50.45 |
| Protein Tyrosine Phosphatases | 2021-2025 | 733 | US 216 | 44.06 |
